Virus-Like Particles (VLPs) in Animal Immunization for Antibody Drug Development

Introduction to VLPs (Virus-Like Particles)

Virus-like particles (VLPs) are robust protein scaffolds that mimic the form and size of viruses but lack genetic material, making them non-infectious and inherently safe for use in immunization. These self-assembling protein-based particles exhibit repetitive epitopes and well-defined geometries, enabling robust activation of the immune system. 

In therapeutic antibody development, VLPs are used as antigen delivery systems to present immunogenic epitopes, eliciting targeted and strong humoral immune responses. 

The Role of VLPs in Antibody Generation

As Antigen Delivery Systems

VLPs are ideal platforms for multivalent antigen display, allowing researchers to present a dense array of epitopes in a highly immunogenic format, with their multivalency improving B-cell activation. Unlike many other subunit vaccines, VLPs can stimulate both humoral and cellular immune pathways without adjuvants.

Recent advancements have explored alternative VLP platforms, such as DNA-based VLPs (DNA-VLPs). Unlike protein-based VLPs (P-VLPs), DNA-VLPs avoid inducing immune responses against the scaffold itself, which can dilute the immune system's focus on the target antigen. For example, DNA-VLPs displaying the receptor binding domain (RBD) of SARS-CoV-2 effectively elicited neutralizing antibodies in animal models without generating class-switched antibodies against the DNA scaffold.

Antibody Quality

High-affinity antibodies are used in therapeutic applications for their target specificity and minimal off-target effects. VLPs, particularly those designed for mammalian immunization, can mimic human antigens more effectively through post-translational modifications which helps in generating functional antibodies, such as monoclonal antibodies targeting cancer or infectious diseases.

Advantages of Using VLPs in Animal Models for Antibody Drug Discovery

Safety

VLPs are non-replicative and have no genome, eliminating the risks associated with live attenuated or inactivated viruses. Their high safety profile ensures suitability for veterinary and human applications, including in immunocompromised subjects.

Customizability

VLP platforms are remarkably versatile. They can be engineered to display specific epitopes or antigens, including tumor-associated antigens or viral proteins. For example, VLPs displaying foreign antigens can function as vectors in subunit vaccines, expanding their applications to infectious diseases, cancer, and chronic conditions.

High Immunogenicity

VLPs exhibit repetitive, dense surface epitopes that closely mimic native viruses, allowing for strong activation of B-cells and T-cells. This makes VLPs particularly advantageous for weakly immunogenic targets, which might otherwise fail to elicit an adequate response in animal models.

References:

1. Crisci, E., Bárcena, J., & Montoya, M. (2012). Virus-like particle-based vaccines for animal viral infections. Inmunologia (Barcelona, Spain : 1987), 32(3), 102. https://doi.org/10.1016/j.inmuno.2012.08.002

2. Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, Katalani, C., Abbas Hajizade, Easton, A. J., & Ahmadian, G. (2021). Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology, 19(1). https://doi.org/10.1186/s12951-021-00806-7

3. Wamhoff, E., Ronsard, L., Feldman, J., Knappe, G. A., Hauser, B. M., Romanov, A., Case, J. B., Sanapala, S., Lam, E. C., Denis, K. J., Boucau, J., Barczak, A. K., Balazs, A. B., Diamond, M. S., Schmidt, A. G., Lingwood, D., & Bathe, M. (2024). Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds. Nature Communications, 15(1), 1-13. https://doi.org/10.1038/s41467-024-44869-0